Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer

Chung, Jee Min; Jung, Yongsik; Kim, Young‐Pil; Song, Juhun; Kim, Soyeon; Kim, Ji Young; Kwon, Mira; Yoon, Jung Hyun; Kim, Myo-Deok; Lee, Jun-kyoung; Chung, Da-Yoon; Lee, Seo Yun; Kang, Jooseong; Kang, Ho Chul

doi:10.4048/jbc.2018.21.1.87

Cited by 9 publications

(2 citation statements)

References 16 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Profiling of autoantibodies in cancers has paved a potential way for cancer detection and diagnosis it has already been studied for glioma [23], meningioma [24], gastric cancer [26] and triple‐negative breast cancer [25]. In order to understand the disease biology of PAs and their better management, we performed a proteome‐wide autoantibody screening.…”

Section: Discussionmentioning

confidence: 99%

“…They are the first response shown by the immune system against tumour‐specific antigens during the onset of tumorigenesis and also have a longer half‐life, supporting early diagnosis and better prognosis of a tumour [22]. Several studies have been reported using human proteome (HuProt) arrays and have successfully identified autoantibody biomarkers in different types of tumours, including glioma [23], meningioma [24], triple‐negative breast cancer [25] and gastric cancer [26]. To date, no studies are available in PAs to identify early autoantibody biomarkers using this high‐density protein microarray.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of autoantibody signatures in pituitary adenoma patients using human proteome arrays

Banerjee

Ray

Barpanda

et al. 2022

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose To identify the specific diagnostic biomarkers related to pituitary adenomas (PAs), we performed serological antibody profiles for three types of PAs, namely Acromegaly, Cushing's and Nonfunctional Pituitary Adenomas (NFPAs), using the human proteome (HuProt) microarray. This is the first study describing the serum autoantibody profile of PAs. Experimental Design We performed serological autoantibody profiling of four healthy controls, four Acromegaly, three Cushing's and three NFPAs patient samples to obtain their autoantibody profiles, which were used for studying expression, interaction and altered biological pathways. Further, significant autoantibodies of PAs were compared with data available for glioma, meningioma and AAgAtlas for their specificity. Results Autoantibody profile of PAs led to the identification of differentially expressed significant proteins such as AKNAD1 (AT‐Hook Transcription Factor [AKNA] Domain Containing 1), NINJ1 (Nerve injury‐induced protein 1), L3HYPDH (Trans‐3‐hydroxy‐L‐proline dehydratase), RHOG (Rho‐related GTP‐binding protein) and PTP4A1 (Protein Tyrosine Phosphatase Type IVA 1) in Acromegaly. Protein ABR (Active breakpoint cluster region‐related protein), ST6GALNAC6 (ST6 N‐acetylgalactosaminide alpha‐2, 6‐sialyltransferase 6), NOL3 (Nucleolar protein 3), ANXA8 (Annexin A8) and POLR2H (RNA polymerase II, I and III subunit H) showed an antigenic response in Cushing's patient's serum samples. Protein dipeptidyl peptidase 3 (DPP3) and reticulon‐4 (RTN4) exhibited a very high antigenic response in NFPA patients. These proteins hold promise as potential autoantibody biomarkers in PAs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of autoantibody signatures in pituitary adenoma patients using human proteome arrays

Banerjee

Ray

Barpanda

et al. 2022

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

Glutaredoxin: Discovery, redox defense and much more

et al. 2021

View full text Add to dashboard Cite

An Autoantigen Atlas from Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19

Wang¹,

Zhang

Mw³

et al. 2021

Preprint

View full text Add to dashboard Cite

COVID-19 is accompanied by a myriad of both transient and long-lasting autoimmune responses. Dermatan sulfate (DS), a glycosaminoglycan crucial for wound healing, has unique affinity for autoantigens (autoAgs) from apoptotic cells. DS-autoAg complexes are capable of stimulating autoreactive B cells and autoantibody production. Using DS affinity, we identified an autoantigenome of 408 proteins from human fetal lung fibroblast HFL11 cells, at least 231 of which are known autoAgs. Comparing with available COVID data, 352 proteins of the autoantigenome have thus far been found to be altered at protein or RNA levels in SARS-Cov-2 infection, 210 of which are known autoAgs. The COVID-altered proteins are significantly associated with RNA metabolism, translation, vesicles and vesicle transport, cell death, supramolecular fibrils, cytoskeleton, extracellular matrix, and interleukin signaling. They offer clues to neurological problems, fibrosis, smooth muscle dysfunction, and thrombosis. In particular, 150 altered proteins are related to the nervous system, including axon, myelin sheath, neuron projection, neuronal cell body, and olfactory bulb. An association with the melanosome is also identified. The findings from our study illustrate a strong connection between viral infection and autoimmunity. The vast number of COVID-altered proteins with propensity to become autoAgs offers an explanation for the diverse autoimmune complications in COVID patients. The variety of autoAgs related to mRNA metabolism, translation, and vesicles raises concerns about potential adverse effects of mRNA vaccines. The COVID autoantigen atlas we are establishing provides a detailed molecular map for further investigation of autoimmune sequelae of the pandemic.Summary sentenceAn autoantigenome by dermatan sulfate affinity from human lung HFL1 cells may explain neurological and autoimmune manifestations of COVID-19

show abstract

Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer

Cited by 9 publications

References 16 publications

Evaluation of autoantibody signatures in pituitary adenoma patients using human proteome arrays

Evaluation of autoantibody signatures in pituitary adenoma patients using human proteome arrays

Glutaredoxin: Discovery, redox defense and much more

An Autoantigen Atlas from Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19

Contact Info

Product

Resources

About